The PI3Kδ-inhibitor idelalisib is approved for patient use in chronic lymphocytic leukaemia, small lymphocytic lymphoma and follicular lymphoma, and several other PI3K inhibitors are undergoing phase II–III trials [156]. The gene discussed is PIK3CA; the disease is follicular lymphoma.